Literature DB >> 25066792

Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.

M Harrow1, T H Jobe1, R N Faull1.   

Abstract

BACKGROUND: This research assesses whether multi-year treatment with antipsychotic medications reduces or eliminates psychosis in schizophrenia. It provides 20 years of longitudinal data on the frequency and severity of psychotic activity in samples of schizophrenia patients (SZ) treated versus those not treated with antipsychotic medications.
METHOD: A total of 139 early young schizophrenia and mood-disordered patients were assessed at index hospitalization and then reassessed six times over 20 years for psychosis and other major variables.
RESULTS: At each follow-up assessment over the 20 years, a surprisingly high percentage of SZ treated with antipsychotics longitudinally had psychotic activity. More than 70% of SZ continuously prescribed antipsychotics experienced psychotic activity at four or more of six follow-up assessments over 20 years. Longitudinally, SZ not prescribed antipsychotics showed significantly less psychotic activity than those prescribed antipsychotics (p < 0.05).
CONCLUSIONS: The 20-year data indicate that, longitudinally, after the first few years, antipsychotic medications do not eliminate or reduce the frequency of psychosis in schizophrenia, or reduce the severity of post-acute psychosis, although it is difficult to reach unambiguous conclusions about the efficacy of treatment in purely naturalistic or observational research. Longitudinally, on the basis of their psychotic activity and the disruption of functioning, the condition of the majority of SZ prescribed antipsychotics for multiple years would raise questions as to how many of them are truly in remission.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25066792     DOI: 10.1017/S0033291714000610

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  20 in total

1.  The public debate on psychotropic medication and changes in attitudes 1990-2011.

Authors:  Matthias C Angermeyer; Sandra Van der Auwera; Herbert Matschinger; Mauro G Carta; Sebastian E Baumeister; Georg Schomerus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-11-28       Impact factor: 5.270

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 3.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

4.  Influence of More Than 5 Years of Continuous Exposure to Antipsychotics on Cerebral Functional Connectivity of Chronic Schizophrenia.

Authors:  Qi Miao; Chengcheng Pu; Zhijiang Wang; Chao-Gan Yan; Chuan Shi; Qingjiu Cao; Xijin Wang; Zhang Cheng; Xue Han; Lei Yang; Yunyao Lai; Yanbo Yuan; Hong Ma; Keqing Li; Nan Hong; Xin Yu
Journal:  Can J Psychiatry       Date:  2020-02-06       Impact factor: 4.356

Review 5.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

6.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

Review 7.  Epigenetic Mechanisms of Serotonin Signaling.

Authors:  Terrell Holloway; Javier González-Maeso
Journal:  ACS Chem Neurosci       Date:  2015-03-10       Impact factor: 4.418

8.  Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China.

Authors:  Mao-Sheng Ran; Xue Weng; Cecilia Lai-Wan Chan; Eric Yu-Hai Chen; Cui-Ping Tang; Fu-Rong Lin; Wen-Jun Mao; Shi-Hui Hu; Yue-Qin Huang; Meng-Ze Xiang
Journal:  Br J Psychiatry       Date:  2015-09-17       Impact factor: 9.319

Review 9.  Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.

Authors:  Susan F Sonnenschein; A Grace
Journal:  Expert Opin Ther Targets       Date:  2020-11-26       Impact factor: 6.902

10.  Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.

Authors:  Georgios Schoretsanitis; John M Kane; Christoph U Correll; Jose M Rubio
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.